Search
Search
About
Log in
Join
Experiences with
Ozanimod
Posts
Communities
4 public posts
Filter results
Ozanimod (Zeposia) Controls MS Disease Activity Regardless of Age
[i]
Clinical and radiologic measures of disease activity remained stable or improved for relapsing multiple sclerosis (RMS) patients in all age groups over 7 to 8 years of continuous treatment with
(Zeposia).
[i]
Clinical and radiologic measures of disease activity remained stable or improved for relapsing multiple sclerosis (RMS) patients in all age groups over 7 to 8 years of continuous treatment with
(Zeposia).
BettysMom
in
My MSAA Community
3 months ago
MSAA News Update - Launch of Zeposia® (ozanimod) Announced
My MSAA Community members, Please see info from MSAA on the recently-announced news of the commercial launch and availability of Zeposia® (
ozanimod
) for the treatment of adults with relapsing forms of multiple sclerosis - learn more in the Latest News link below: https://mymsaa.org/news/launch-of-zeposia-announced
My MSAA Community members, Please see info from MSAA on the recently-announced news of the commercial launch and availability of Zeposia® (
ozanimod
) for the treatment of adults with relapsing forms of multiple sclerosis - learn more in the Latest News link below: https://mymsaa.org/news/launch-of-zeposia-announced
johnMSAA
Partner
in
My MSAA Community
4 years ago
MSAA News Update - FDA Approves Zeposia® (ozanimod)
Please see below for a link to MSAA's latest news update about the FDA approval of Zeposia® (
ozanimod
) for relapsing forms of MS: https://mymsaa.org/news/fda-approves-zeposia-for-relapsing-ms Thank you, Emily
Please see below for a link to MSAA's latest news update about the FDA approval of Zeposia® (
ozanimod
) for relapsing forms of MS: https://mymsaa.org/news/fda-approves-zeposia-for-relapsing-ms Thank you, Emily
MSAA_Staff
in
My MSAA Community
4 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
FDA Approves Zeposia (Ozanimod), Oral Therapy for All with Relapsing MS
forms of multiple sclerosis will have another oral treatment option with meaningful efficacy to help address the disease’s hallmark relapses and brain lesions,” said Samit Hirawat, MD, the company’s chief medical officer. https://multiplesclerosisnewstoday.com/news-posts/2020/03/26/fda-approves-zeposia-
ozanimod
-oral-rrms-active-spms-cis-therapy
forms of multiple sclerosis will have another oral treatment option with meaningful efficacy to help address the disease’s hallmark relapses and brain lesions,” said Samit Hirawat, MD, the company’s chief medical officer. https://multiplesclerosisnewstoday.com/news-posts/2020/03/26/fda-approves-zeposia-
ozanimod
-oral-rrms-active-spms-cis-therapy
bxrmom
in
My MSAA Community
4 years ago
Filter results
Clear filters
Posted in
All communities
My MSAA Community
4 results
Sort by
Most Relevant
Newest